Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-WEEK RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, MULTICENTRE CLINICAL TRIAL, TO ASSESS THE EFFICACY AND SAFETY OF 200 μg OF THE ANTICHOLINERGIC LAS 34273 COMPARED TO PLACEBO, BOTH ADMINISTERED ONCE DAILY BY INHALATION, IN THE MAINTENANCE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE, STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Next Previous
X
Search
Trial Profile

A 52-WEEK RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, MULTICENTRE CLINICAL TRIAL, TO ASSESS THE EFFICACY AND SAFETY OF 200 μg OF THE ANTICHOLINERGIC LAS 34273 COMPARED TO PLACEBO, BOTH ADMINISTERED ONCE DAILY BY INHALATION, IN THE MAINTENANCE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE, STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCLAIM-I; ACCLAIM/COPD-I
  • Sponsors Almirall S.A.

    • Most Recent Events

    • 03 Nov 2012 Planned number of patients 1260 added as reported by European Clinical Trials Database.
    • 12 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society.
    • 12 Sep 2009 Primary endpoint 'Forced expiratory volume in 1 second' has been met according to results presented at the 19th Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top